http://www.hbver.com/- 战胜乙肝网

电影投资 和田玉手镯 会员登录 会员登录 会员注册 会员注册   
搜索: 您现在的位置: 战胜乙肝网>> 文章中心>> 医疗进展>> 理论研究>> 内容

乙肝感染慢性化机制研究获进展

更新时间:2012年01月13日22:49:35    作者:战胜乙肝网    文章来源:生物谷
点击次数:
手机版地址:乙肝感染慢性化机制研究获进展

Hepatology:孟颂东等乙肝感染慢性化机制研究获进展

作者:中科院微生物研究所 来源:中科院微生物研究所

近日,国际杂志Hepatology在线刊登了中科院微生物研究所研究人员的最新研究进展“Loss of MiR-122 expression in patients with hepatitis B enhances hepatitis B virus replication through cyclin G1 modulated P53 activity,”,文章中,作者揭示了乙肝感染慢性化机制的相关研究。

全世界有3.5亿人慢性感染乙肝病毒(HBV),在我国感染人群约9300万,乙肝慢性引起急、慢性病毒性肝炎,与肝纤维化、肝癌的发生发展密切相关,严重威胁人类的健康。病毒感染人体后,病毒与宿主之间的相互作用决定感染的结局和疾病转归。然而,迄今为止,病毒逃逸宿主防御及乙肝慢性化机制并不清楚。因此,研究病毒与宿主因子相互作用及病毒持续感染的分子机制,将有助于设计治疗慢性乙肝的新的靶向药物。

microRNA-122 (miR-122)在肝脏中特异性表达,而且是肝细胞中丰度最高的小RNA,在肝脏功能和病理中发挥重要作用。在“973”、国家自然基金等项目的资助下,中科院微生物研究所孟颂东研究员课题组新近的研究发现,miR-122作为宿主限制性因子明显抑制病毒复制,而在乙肝慢性感染中由于慢性炎症和病毒感染引起miR-122下调。进一步研究查明,miR-122通过cyclin G1/p53通路对病毒复制起调控作用。

基于以上研究,课题组提出乙肝感染慢性化的新机制:乙肝慢性感染下调宿主限制性小RNA,通过miR-122-cyclin G1/p53-病毒增强子通路促进病毒的表达与复制。这为进一步了解HBV病毒的持续感染机制和肝癌发生途径提供了新的依据和阐释,同时提出miR-122作为治疗慢性乙肝的潜在新一代药物的可行性。(生物谷Bioon.com)


doi:10.1002/hep.24809
PMC:
PMID:
Loss of MiR-122 expression in patients with hepatitis B enhances hepatitis B virus replication through cyclin G1 modulated P53 activity

Saifeng Wang1,†, Lipeng Qiu1,†, Xiaoli Yan1, Wensong Jin1, Yanzhong Wang1, Lizhao Chen1, Erjie Wu1, Xin Ye1, George F Gao1, Fusheng Wang2, Yu Chen3, Zhongping Duan3,*,‡, Songdong Meng1,*


Hepatitis B virus (HBV) causes chronic infection in about 350 million people worldwide. Given the important role of the most abundant liver-specific microRNA miR-122 in hepatic function and liver pathology, here we investigated the potential role and mechanism of miR-122 in regulating HBV replication. We found that miR-122 expression in liver was significantly down-regulated in patients with HBV infection compared with healthy controls, and the miR-122 levels were negatively correlated with intrahepatic viral load and hepatic necroinflammation. The depletion of endogenous miR-122 by its antisense inhibitor led to enhanced HBV replication whereas over-expression of miR-122 by transfection of mimic or its expression vector inhibited viral production. We next identified cyclin G1 as a miR-122 target from multiple candidate target genes which is involved in the regulation of HBV replication. Over-expression and knock-down studies both showed that cyclin G1 regulated viral replication in HBV transfected cells. We also observed that cyclin G1 expression was up-regulated in HBV infected patients, and cyclin G1 levels were inversely associated with miR-122 expression in liver tissues. Using co-immunoprecipitation, luciferase reporter system and electrophoretic mobility shift assay (EMSA), we further demonstrated that cyclin G1 specifically interacted with p53, and this interaction blocked the specific binding of p53 to HBV enhancer elements and simultaneously abrogated p53-mediated inhibition of HBV transcription. Finally, we showed miR-122 suppressed HBV replication in p53 wild-type cells but not in null isogenic cells. Conclusion: miR-122 down-regulates its target cyclin G1, thus interrupts interaction between cyclin G1 and p53, and abrogates p53-mediated inhibition of HBV replication. Our work showed that miR-122 down-regulation induced by HBV infection can impact HBV replication and possibly contribute to viral persistence and carcinogenesis.

Tags:慢性化机制,研究,进展  
责任编辑:战胜乙肝网

网友评论

(以下评论仅代表网友意见,与本站立场无关)